Ahmed, Mahmoud Salama http://orcid.org/0000-0002-5600-4698
Nguyen, Ngoc Uyen Nhi http://orcid.org/0000-0003-0694-3176
Nakada, Yuji
Hsu, Ching-Cheng http://orcid.org/0000-0002-8804-6171
Farag, Ayman
Lam, Nicholas T. http://orcid.org/0000-0002-9446-7378
Wang, Ping
Thet, Suwannee
Menendez-Montes, Ivan http://orcid.org/0000-0001-5252-9502
Elhelaly, Waleed M.
Lou, Xi
Secco, Ilaria http://orcid.org/0000-0002-3920-7565
Tomczyk, Mateusz http://orcid.org/0000-0001-9322-748X
Zentilin, Lorena
Pei, Jimin
Cui, Miao
Dos Santos, Matthieu
Liu, Xiaoye
Liu, Yan
Zaha, David
Walcott, Gregory
Tomchick, Diana R. http://orcid.org/0000-0002-7529-4643
Xing, Chao http://orcid.org/0000-0002-1838-0502
Zhang, Cheng Cheng http://orcid.org/0000-0003-4763-3887
Grishin, Nick V.
Giacca, Mauro http://orcid.org/0000-0003-2927-7225
Zhang, Jianyi http://orcid.org/0000-0002-3955-6554
Sadek, Hesham A. http://orcid.org/0000-0002-4745-366X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1P01HL160476-01A1, R35 HL166563-01, NIH P01HL160488)
Fondation Leducq (Redox Leducq)
Foundation for the National Institutes of Health (R01GM119336)
American Heart Association (856552, 19POST34450039)
Article History
Received: 10 November 2023
Accepted: 6 February 2024
First Online: 11 March 2024
Competing interests
: M.G. is founder, consultant, member of the board and equity holder in Forcefield Therapeutics, Heqet Therapeutics and Purespring Therapeutics. All other authors declare no competing interests.